被冻结的217万元占公司募集资金净额的0.13%，该资金主要为尚未到期的合同尾款。 近日，昊帆生物（301393）发布公告称，近日公司发现部分募集资金专项账户和现金管理专用结算账户 因财产保全被司法冻结。 被冻结的募集资金专项账户在中国银行的实际冻结金额为217万元，冻结原因是由于公司与予君生物的 股权转让合同纠纷，予君生物请求法院采取财产保全措施。 （昊帆生物公告） ...

证券代码：301393 证券简称：昊帆生物 公告编号：2026-002 苏州昊帆生物股份有限公司 关于部分募集资金账户被冻结的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 苏州昊帆生物股份有限公司（以下简称"公司"或"昊帆生物"）于 2026 年 2 月 11 日办理银行相关业务时，发现部分募集资金专项账户和现金管理专用 结算账户因财产保全被司法冻结，现将相关情况公告如下： | 账户 | | | | 实际冻结 | | --- | --- | --- | --- | --- | | 主体 | 开户银行 | 银行账号 | 账户性质 | 金额 | | | | | | （万元） | | 昊帆 | 中国银行股份有限公司苏州高 | 530079465004 | 募集资金专项账户 | 216.85 | | 生物 | 新技术产业开发区支行 | | | | | 昊帆 | 中国建设银行股份有限公司苏 | 32250198864709 | 募集资金现金管理 | 0.00 | | 生物 | 州新浒支行 | 888999 | 专用结算账户 | | 二、被冻结的原因 ...

Market Overview - The biopharmaceutical sector increased by 1.27% on February 3, with Wanzhe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Stock Performance - Wanzhe Co., Ltd. (000534) closed at 30.65, with a rise of 10.01% and a trading volume of 313,500 shares, amounting to a transaction value of 921 million yuan [1] - Other notable performers included ST Weiming (002581) with a 5.01% increase, closing at 7.55, and Nearshore Protein (688137) with a 4.84% increase, closing at 44.20 [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 255 million yuan from institutional investors and 153 million yuan from retail investors, while retail investors saw a net inflow of 408 million yuan [2] - The capital flow for individual stocks showed that Wanzhe Co., Ltd. had a net outflow of 50.83 million yuan from institutional investors, while retail investors contributed a net inflow of 15.59 million yuan [3] Individual Stock Analysis - Eurolin Biotech (688319) had a net inflow of 21.61 million yuan from institutional investors, while ST Weiming (002581) saw a significant net inflow of 13.51 million yuan [3] - Conversely, major outflows were noted in Wanzhe Co., Ltd. and other stocks, indicating varied investor sentiment across the sector [3]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

证券日报网讯 1月30日，昊帆生物在互动平台回答投资者提问时表示，公司严格按照相关法律法规、规 则要求进行信息披露，若触及披露标准，公司将及时履行信息披露义务。 （文章来源：证券日报） ...

证券日报网讯 1月22日，昊帆生物发布公告称，近日，公司全资子公司淮安昊帆生物医药有限公司开立 了募集资金现金管理专用结算账户。鉴于公司及全资子公司安徽昊帆生物有限公司前期设立的部分募集 资金现金管理专用结算账户中相关理财产品已全部到期赎回，且无后续使用计划，因此根据相关规定， 公司于近日办理完毕上述募集资金现金管理专用结算账户的注销手续。 （编辑 任世碧） ...

账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 苏州昊帆生物股份有限公司（以下简称"公司"或"昊帆生物"）于 2025 年 4 月 9 日召开第四届董事会第七次会议及第四届监事会第五次会议，并于 2025 年 5 月 9 日召开 2024 年度股东大会，审议通过了《关于使用闲置募集资金和闲 置自有资金进行现金管理的议案》，同意公司使用额度不超过 10 亿元的闲置募 集资金和不超过 14 亿元的闲置自有资金进行现金管理。使用期限自股东大会审 议通过之日起 12 个月内有效。在前述额度和期限内，资金可以循环滚动使用。 具体内容详见公司于 2025 年 4 月 11 日在巨潮资讯网（www.cninfo.com.cn）披露 的《关于使用闲置募集资金和闲置自有资金进行现金管理的公告》（公告编号： 2025-014）。 证券代码：301393 证券简称：昊帆生物 公告编号：2026-001 苏州昊帆生物股份有限公司 关于开立和注销部分募集资金现金管理专用结算 一、开立募集资金现金管理专用结算账户的情况 近日，公司全资子公司淮安昊帆生物医药有限公司（以下简称" ...

Group 1 - The core point of the news is that Haofan Bio experienced a decline of 5.02% in its stock price, closing at 54.50 yuan per share, with a trading volume of 1.07 billion yuan and a turnover rate of 4.60%, resulting in a total market capitalization of 58.86 billion yuan [1] - Haofan Bio, established on December 2, 2003, and listed on July 12, 2023, is located in Suzhou, Jiangsu Province, and specializes in the research and sales of peptide synthesis reagents, protein crosslinkers, and molecular building blocks [1] - The revenue composition of Haofan Bio's main business includes peptide synthesis reagents at 81.89%, general molecular building blocks at 10.99%, protein reagents at 6.11%, and other products at 1.01% [1] Group 2 - Among the top circulating shareholders of Haofan Bio, a fund under Huatai-PineBridge holds a significant position, with the Huatai-PineBridge Healthcare Mixed Fund (470006) increasing its holdings by 264,300 shares to a total of 866,800 shares, representing 2.06% of the circulating shares [2] - The Huatai-PineBridge Healthcare Mixed Fund (470006) was established on September 21, 2010, with a latest scale of 2.486 billion yuan, achieving a year-to-date return of 10.53% and a one-year return of 37.91% [2] - The fund manager of Huatai-PineBridge Healthcare Mixed Fund is Zheng Lei, who has a tenure of 11 years and 33 days, with the fund's total asset scale at 8.093 billion yuan [3]

国联民生证券承销保荐有限公司 现场检查手段：查阅募集资金监管协议及募集资金管理制度；查阅募集资金存放 银行对账单、募集资金使用台账；查阅现金管理相关决策文件、募集资金账户划 款凭证资料；核查与募集资金使用相关的会议记录及公告；查阅公司利用闲置募 集资金进行现金管理的有关协议 | 1.是否在募集资金到位后一个月内签订三方监管协议 | √ | | | --- | --- | --- | | 2.募集资金三方监管协议是否有效执行 | √ | | | 3.募集资金是否不存在第三方占用、委托理财等情形 | √ | | | 4.是否不存在未履行审议程序擅自变更募集资金用途、 | | | | 暂时补充流动资金、置换预先投入、改变实施地点等情 | √ | | | 形 | | | | 5.使用闲置募集资金暂时补充流动资金、将募集资金投 | | | | 向变更为永久性补充流动资金或者使用超募资金补充 | √ | | | 流动资金或者偿还银行贷款的，公司是否未在承诺期 | | | | 间进行风险投资 | | | | 6.募集资金使用与已披露情况是否一致，项目进度、投 | | | | 资效益是否与招股说明书等相符 | √ | | | ...

国联民生证券承销保荐有限公司 关于苏州昊帆生物股份有限公司 2025 年度持续督导培训情况报告 深圳证券交易所： 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规定，作 为苏州昊帆生物股份有限公司（以下简称"昊帆生物"或"公司"）首次公开发行股 票并在创业板上市的保荐机构，国联民生证券承销保荐有限公司（以下简称"国联民 生承销保荐"或"保荐机构"）对昊帆生物进行了 2025 年度持续督导培训。现将培训 情况报告如下： 一、培训基本情况 （七）培训对象：公司董事、高级管理人员、中层以上管理人员及上市公司控股 股东和实际控制人等相关人员。 二、培训内容 （此页无正文，为《国联民生证券承销保荐有限公司关于苏州昊帆生物股份有限公司 2025 年度持续督导培训情况报告》之签章页 ) BAN In 71 7 保荐代表人: 刘永泓 都 航 国联民生证券 2026 H and 1 the （一）保荐机构：国联民生证券承销保荐有限公司 （二）保荐代表人：邵航、刘永泓 （三）培训时间：2026 年 1 月 6 日 （四）培训方式 ...